Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 19 2026
0mins
Should l Buy 02142?
Source: PRnewswire
- Strategic Partnership Upgrade: Harbour BioMed exercised its warrant through a wholly-owned subsidiary to acquire approximately 3.8% of Spruce Biosciences, marking a shift from a traditional licensing relationship to a strategic partnership aimed at accelerating the development of transformative therapies.
- Equity Structure Change: Following this transaction, Harbour BioMed holds about 3.8% of Spruce's outstanding shares and 3.1% of fully diluted shares, enhancing its influence over Spruce and facilitating collaborative projects between the two companies.
- R&D Collaboration Prospects: This acquisition aligns with the collaboration to advance the development of SPR202, a monoclonal antibody targeting various disorders, showcasing Harbour BioMed's R&D potential in immunology and oncology.
- Technological Platform Advantage: Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, and HBICE® technology provide a competitive edge in antibody discovery and development, enabling tumor-killing effects that traditional therapies cannot achieve.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy 02142?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on 02142
Wall Street analysts forecast 02142 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02142 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.030
Low
Averages
High
Current: 11.030
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences
- Strategic Partnership Upgrade: Harbour BioMed exercised its warrant through a wholly-owned subsidiary to acquire approximately 3.8% of Spruce Biosciences, marking a shift from a traditional licensing relationship to a strategic partnership aimed at accelerating the development of transformative therapies.
- Equity Structure Change: Following this transaction, Harbour BioMed holds about 3.8% of Spruce's outstanding shares and 3.1% of fully diluted shares, enhancing its influence over Spruce and facilitating collaborative projects between the two companies.
- R&D Collaboration Prospects: This acquisition aligns with the collaboration to advance the development of SPR202, a monoclonal antibody targeting various disorders, showcasing Harbour BioMed's R&D potential in immunology and oncology.
- Technological Platform Advantage: Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, and HBICE® technology provide a competitive edge in antibody discovery and development, enabling tumor-killing effects that traditional therapies cannot achieve.
See More
Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership
- Share Acquisition: Harbour BioMed exercised its warrant through a wholly-owned subsidiary to acquire approximately 3.8% of Spruce Biosciences' outstanding shares, further solidifying its market position in the biopharmaceutical sector.
- Strategic Partnership Upgrade: This transaction marks a shift in the relationship between Harbour BioMed and Spruce from a traditional licensor-licensee model to a true strategic partnership aimed at accelerating the development of transformative therapies for patients worldwide.
- R&D Collaboration: The acquisition is linked to a licensing and collaboration agreement with HBM Alpha Therapeutics, focusing on advancing the development of SPR202, a monoclonal antibody with significant clinical potential for various disorders.
- Technological Platform Advantage: Harbour BioMed leverages its proprietary antibody technology platform, Harbour Mice®, along with HBICE® and HBICATM technologies, to build a highly efficient antibody discovery engine that drives the development of next-generation therapeutic antibodies.
See More
Harbour BioMed Partners with Lannacheng for Next-Gen Radionuclide Drug Development
- Strategic Collaboration: Harbour BioMed has entered a long-term strategic partnership with Lannacheng to jointly advance the development of next-generation radionuclide drug conjugates (RDCs), leveraging their respective resources and strengths to enhance the efficiency of tumor-targeted therapies.
- Technological Advantage: RDCs utilize tumor antigen-specific ligands to deliver radionuclides directly to tumor lesions, significantly reducing damage to surrounding healthy tissues and providing a more targeted treatment option compared to conventional radiotherapy.
- R&D Integration: The collaboration combines Harbour BioMed's Harbour Mice® platform with Lannacheng's radiopharmaceutical R&D capabilities, aiming to accelerate the development of more precise and safe cancer therapies, thereby improving patient outcomes.
- Market Potential: This partnership not only aims to drive new drug development but also brings new hope to cancer patients worldwide, highlighting both companies' innovative potential and competitive strength in the biopharmaceutical sector.
See More
Harbour BioMed Enters Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- Strategic Collaboration: Harbour BioMed has established a long-term strategic partnership with Lannacheng to jointly advance the development of next-generation radionuclide drug conjugates (RDCs), aiming to enhance the precision and efficacy of cancer therapies.
- Technological Advantage: Harbour BioMed's Harbour Mice® platform generates fully human monoclonal antibodies, and when combined with Lannacheng's radiopharmaceutical R&D capabilities, is expected to significantly improve targeted drug delivery efficiency while reducing drug-related toxicity.
- Market Potential: RDCs deliver radionuclides directly to tumor lesions via tumor antigen-specific ligands, effectively minimizing damage to surrounding healthy tissues, and hold potential for overcoming tumor heterogeneity and drug resistance, indicating a broad market outlook.
- Innovative Integration: This collaboration will integrate both parties' strengths in antibody discovery and radiopharmaceutical development, accelerating the creation of safer and more effective cancer treatment solutions, thereby bringing new hope to patients worldwide.
See More
Harbour BioMed Partners with Bristol Myers Squibb for $1.125 Billion Antibody Collaboration
- Strategic Collaboration Agreement: Harbour BioMed has entered into a global strategic collaboration with Bristol Myers Squibb to accelerate the discovery and development of multi-specific antibodies, potentially receiving up to $90 million in initial payments and up to $1.035 billion in development and commercial milestone payments.
- Technological Platform Advantage: This collaboration leverages the Harbour Mice® technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential, thereby strengthening the company's competitive edge in antibody therapeutics.
- Accelerated Clinical Trials: The partnership will also utilize Harbour BioMed's development capabilities in China to conduct early clinical trials, expediting program progress and addressing global patient needs, reflecting the company's strategic positioning in international markets.
- Broad Market Prospects: By collaborating with Bristol Myers Squibb, Harbour BioMed not only expands its product pipeline but also benefits from the latter's expertise in drug discovery and development, driving the launch of transformative therapies and further solidifying its position in the biopharmaceutical industry.
See More
HBM HOLDINGS-B Forms Strategic Partnership with Bristol Myers Squibb, Potentially Earning Up to US$1.035B in Milestone Payments and Royalties
Stock Performance: HBM HOLDINGS-B (02142.HK) experienced a decline of 3.849%, with a short selling amount of $12.54 million and a ratio of 21.210%.
Strategic Collaboration: HBM HOLDINGS-B has entered a multi-year global collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies.
Financial Terms: The agreement could yield HBM HOLDINGS-B up to $90 million in initial payments, with potential development and commercial milestones totaling up to $1.035 billion.
Royalty Structure: HBM HOLDINGS-B may also receive tiered royalties if Bristol Myers Squibb decides to advance all potential programs under the collaboration.
See More
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences
- Strategic Partnership Upgrade: Harbour BioMed exercised its warrant through a wholly-owned subsidiary to acquire approximately 3.8% of Spruce Biosciences, marking a shift from a traditional licensing relationship to a strategic partnership aimed at accelerating the development of transformative therapies.
- Equity Structure Change: Following this transaction, Harbour BioMed holds about 3.8% of Spruce's outstanding shares and 3.1% of fully diluted shares, enhancing its influence over Spruce and facilitating collaborative projects between the two companies.
- R&D Collaboration Prospects: This acquisition aligns with the collaboration to advance the development of SPR202, a monoclonal antibody targeting various disorders, showcasing Harbour BioMed's R&D potential in immunology and oncology.
- Technological Platform Advantage: Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, and HBICE® technology provide a competitive edge in antibody discovery and development, enabling tumor-killing effects that traditional therapies cannot achieve.
See More
Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership
- Share Acquisition: Harbour BioMed exercised its warrant through a wholly-owned subsidiary to acquire approximately 3.8% of Spruce Biosciences' outstanding shares, further solidifying its market position in the biopharmaceutical sector.
- Strategic Partnership Upgrade: This transaction marks a shift in the relationship between Harbour BioMed and Spruce from a traditional licensor-licensee model to a true strategic partnership aimed at accelerating the development of transformative therapies for patients worldwide.
- R&D Collaboration: The acquisition is linked to a licensing and collaboration agreement with HBM Alpha Therapeutics, focusing on advancing the development of SPR202, a monoclonal antibody with significant clinical potential for various disorders.
- Technological Platform Advantage: Harbour BioMed leverages its proprietary antibody technology platform, Harbour Mice®, along with HBICE® and HBICATM technologies, to build a highly efficient antibody discovery engine that drives the development of next-generation therapeutic antibodies.
See More
Harbour BioMed Partners with Lannacheng for Next-Gen Radionuclide Drug Development
- Strategic Collaboration: Harbour BioMed has entered a long-term strategic partnership with Lannacheng to jointly advance the development of next-generation radionuclide drug conjugates (RDCs), leveraging their respective resources and strengths to enhance the efficiency of tumor-targeted therapies.
- Technological Advantage: RDCs utilize tumor antigen-specific ligands to deliver radionuclides directly to tumor lesions, significantly reducing damage to surrounding healthy tissues and providing a more targeted treatment option compared to conventional radiotherapy.
- R&D Integration: The collaboration combines Harbour BioMed's Harbour Mice® platform with Lannacheng's radiopharmaceutical R&D capabilities, aiming to accelerate the development of more precise and safe cancer therapies, thereby improving patient outcomes.
- Market Potential: This partnership not only aims to drive new drug development but also brings new hope to cancer patients worldwide, highlighting both companies' innovative potential and competitive strength in the biopharmaceutical sector.
See More
Harbour BioMed Enters Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- Strategic Collaboration: Harbour BioMed has established a long-term strategic partnership with Lannacheng to jointly advance the development of next-generation radionuclide drug conjugates (RDCs), aiming to enhance the precision and efficacy of cancer therapies.
- Technological Advantage: Harbour BioMed's Harbour Mice® platform generates fully human monoclonal antibodies, and when combined with Lannacheng's radiopharmaceutical R&D capabilities, is expected to significantly improve targeted drug delivery efficiency while reducing drug-related toxicity.
- Market Potential: RDCs deliver radionuclides directly to tumor lesions via tumor antigen-specific ligands, effectively minimizing damage to surrounding healthy tissues, and hold potential for overcoming tumor heterogeneity and drug resistance, indicating a broad market outlook.
- Innovative Integration: This collaboration will integrate both parties' strengths in antibody discovery and radiopharmaceutical development, accelerating the creation of safer and more effective cancer treatment solutions, thereby bringing new hope to patients worldwide.
See More
Harbour BioMed Partners with Bristol Myers Squibb for $1.125 Billion Antibody Collaboration
- Strategic Collaboration Agreement: Harbour BioMed has entered into a global strategic collaboration with Bristol Myers Squibb to accelerate the discovery and development of multi-specific antibodies, potentially receiving up to $90 million in initial payments and up to $1.035 billion in development and commercial milestone payments.
- Technological Platform Advantage: This collaboration leverages the Harbour Mice® technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential, thereby strengthening the company's competitive edge in antibody therapeutics.
- Accelerated Clinical Trials: The partnership will also utilize Harbour BioMed's development capabilities in China to conduct early clinical trials, expediting program progress and addressing global patient needs, reflecting the company's strategic positioning in international markets.
- Broad Market Prospects: By collaborating with Bristol Myers Squibb, Harbour BioMed not only expands its product pipeline but also benefits from the latter's expertise in drug discovery and development, driving the launch of transformative therapies and further solidifying its position in the biopharmaceutical industry.
See More
HBM HOLDINGS-B Forms Strategic Partnership with Bristol Myers Squibb, Potentially Earning Up to US$1.035B in Milestone Payments and Royalties
Stock Performance: HBM HOLDINGS-B (02142.HK) experienced a decline of 3.849%, with a short selling amount of $12.54 million and a ratio of 21.210%.
Strategic Collaboration: HBM HOLDINGS-B has entered a multi-year global collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies.
Financial Terms: The agreement could yield HBM HOLDINGS-B up to $90 million in initial payments, with potential development and commercial milestones totaling up to $1.035 billion.
Royalty Structure: HBM HOLDINGS-B may also receive tiered royalties if Bristol Myers Squibb decides to advance all potential programs under the collaboration.
See More
